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Sir,
Kahler’s disease also known as Multiple Myeloma 
(MM) is a neoplastic plasma-cell disease known 
for its infiltration of malignant plasma cells in the 
bone marrow (BM) accompanied by multiorgan 
dysfunction. The median age at diagnosis is 
approximately 70 years.[1] Less than 2% of the 
patients are younger than 45 years of age at 
diagnosis.[2] MM may present as a diffuse disease 
of the bone (myelomatosis) or may be as a single 
plasmacytoma of bone or as an extramedullary 
plasmacytoma (EMP). The very common thoracic 
involvement by MM is the bone involvement 
or infiltration of the lungs secondary to an 
infection. Although the pulmonary parenchyma 
is quite a rare site of extramedullary involvement 
in MM patients, interstitial lung disease (ILD) as 
a pulmonary manifestation of MM is even rarer. 
Only few proved cases have been reported in the 
literature so far. Therefore, we present a rarest 
case possible of a MM presenting as ILD.
A 40-year-old female with a history of 
hypothyroidism and hypertension had presented 
to the hospital with dyspnea, neck pain, and 
vomiting. Her dyspnea worsened on exertion, with 
no positional variations and no nocturnal/diurnal 
variations and was not associated with any chest 
pain. She was having around 5–6 vomiting per day 
which was non-projectile, non-bilious with the 
absence of blood in vomiting and was also afebrile. 
On physical examination, she was afebrile, pale, 
tachypnoeic (22/min), tachycardic (104 beats/min), 
and with the presence of bilateral basilar crackles.
The patient was initially treated with intravenous 
(IV) fluids, non-invasive ventilation (NIV) 
support, antiemetics, and antacids. Further 
management included carotid massage, 
adenosine, diltiazem, amiodarone infusion for 
paroxysmal supraventricular tachycardia (PSVT), 
IV fluids, diuretics, zoledronic acid, calcitonin, 
and dialysis for hypercalcemia. After MM has 
been confirmed, the patient was treated with 
chemotherapy of six cycles of bortezomib 
(2 mg), dexamethasone (10 mg) regimen, and 
zoledronic acid (4 mg) with each cycle.
Investigations showed anemia (hemoglobin 
of 7.4 g/dl), raised erythrocyte sedimentation 
rate, hypercalcemia (20.60 mg/dl) while 
electrocardiogram showed ST depression, T 
wave inversions in V4-6, Lead II and I, and AVL 
and QS complexes in Lead III.
During the course, despite the ongoing treatment, 
she developed recurrent junctional tachycardia 
and worsening of respiration due to ILD. Chest 
X-ray showed bilateral lung infiltrates. Computed 
tomography (CT) chest showed patchy ground-
glass opacification with interlobular septal 
thickening in bilateral perihilar lung parenchyma 
with multiple osteolytic lesions in vertebrae and 
sternum [Figure 1].
Bronchoalveolar lavage (BAL) tested positive for 
myeloma cells in the lungs bilaterally. BM biopsy 
showed plasma cells. Immunohistochemistry 
(IHC) showed plasma cell population in both 
BAL fluid cell block (positive for CD 138) and BM 
biopsy [Figures 2 and 3].
Plasma protein electrophoresis showed M 
spike (2.74 g/dl) and increased gamma globulin 
(3.41 g/dl) [Figure 4].
Serum immunofixation electrophoresis showed 
IgG kappa chain dominance (148.20 mg/L) and 
increased kappa/lambda ratio (19.32) [Figure 5].
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cycles of dexamethasone (10 mg), bortezomib (2 mg), and 
zoledronic acid (4 mg) regimen.
The patient responded significantly well to the treatment 
with improvement. After four cycles of chemotherapy, plasma 
protein electrophoresis showed a decrease in M spike (0.80 g/
dl) [Figure 6].
CT chest showed a significant improvement [Figure 7].
The patient is currently under regular follow-up since 2 years 
with no new complaints.
MM presenting as ILD has been documented in very rare 
occasions till date. Interestingly, MM has a potential to involve 
the thorax through various ways, but the involvement of the 
pulmonary parenchymal is rather rare. In literature, it was 
observed that MM’s thoracic manifestations included abnormal 
skeleton structure, pleural effusions, diaphragmatic dysfunction 
because of peripheral neuropathy, and plasmacytomas.
In a review conducted by Kintzer et al. on 958 patients with MM, 
the thoracic manifestations were specifically reported.[3] The 
most common manifestation was osteolytic lesions of ribs or 
vertebrae’s which was observed in 267 (28%) patients followed 
by pulmonary infiltrates (95 patients [10%]). Otherwise, the 
pleural effusions were also present in 58 patients (6%) while 
EMPs were observed in 11 (1%). Only four patients from this 
study showed diffuse infiltrates which was thought to be 
caused by plasma cell infiltrate (proven in only one case). This 
explains the rare phenomenon of ILD in case of MM. In the 
present case, the observed diffuse infiltrates throughout the 
lung fields were also caused by plasma cells.
A similar presentation of MM as ILD was reported in a case by 
Ma et al.[4] and Nitu et al.[5]
Standard medical management of symptomatic MM 
involves chemotherapy with or without an autologous 
stem-cell transplant for patients under the age of 70.[6] IV 
administration of bisphosphonates are used in conjunction 
with chemotherapy and have been shown to decrease the 
progression of osteolytic lesions. Bisphosphonate treatment 
is recommended for patients with radiological evidence of 
osteolytic lesions or osteoporosis and is continued monthly for 
a period of 2 years.[7] Supportive therapy for patients with MM 
may include maintenance of fluid and electrolytes with regular 
hydration, erythropoietin and transfusions to replace red blood 
cells and platelets, pain control using analgesics (non-steroidal 
anti-inflammatory drugs are contraindicated due to potential 
for renal complications), promotion of mobility to prevent 
osteoporotic fractures, spinal decompression surgery for spinal 
complications, and radiation therapy for focal skeletal lesions.[8]
Figure 1: Patchy ground-glass opacification with interlobular 
septal thickening in bilateral perihilar lung parenchyma with 
multiple osteolytic lesions in vertebrae and sternum
Figure 2: Bronchoalveolar lavage fluid cell block
Serum beta-2 macroglobulin was 3143 mg/dl. Thus, the 
diagnosis of MM with myeloma cells infiltrates in lung showing 
ILD pattern was made.
The patient was initially treated with IV fluids, NIV support, 
antiemetics, and antacids. Further management included 
carotid massage, adenosine, diltiazem, amiodarone infusion 
for PSVT, calcitonin, IV fluids, diuretics, zoledronic acid, and 
dialysis for hypercalcemia. After the diagnosis of MM was 
confirmed, the patient was started on chemotherapy of six 
Figure 3: Bone marrow biopsy showing monomorphic 
plasma cells with occasional binucleated forms
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The mean overall duration of survival after being diagnosed 
with MM is 33 months with considerable individual 
variation.[9] Negative prognostic indicators include older age, a 
previously diagnosed plasma cell disorder, and key laboratory 
findings.[10] Laboratory findings indicating a worse prognosis 
include elevated β-2 microglobulin, serum albumin, and 
C-reactive protein. The BM cytogenetics can also be used to 
help determine prognosis up on diagnosis.[11]
Lung involvement and pulmonary infiltrates are not common in 
a case of MM. Most of the time, we suspect lung infection. MM 
should be taken into consideration in the differential diagnosis 
of pulmonary infiltration in patients with MM. The possibility 
of myelomatous pulmonary infiltrates should be suspected 
in the absence of fever, failure to respond to antibiotics, and 
resolution to myeloma treatment. Analysis of BAL fluid and 
lung biopsy for the presence of plasma cells and IHC provides 
a means of establishing the diagnosis. Pulmonary involvement 
indicates aggressive nature of the disease. Treatment of MM 
along with supportive care should be started at the earliest in 
these cases.
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